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POINT-COUNTERPOINT
Should Interferon Gamma Release Assays Become the Standard
Method for Screening Patients for Mycobacterium tuberculosis
Infections in the United States?
The Centers for Disease Control and Prevention recently published updated guidelines for the use of
interferon gamma release assays (IGRAs) to detect Mycobacterium tuberculosis. This document gives a balanced
analysis of the strengths and weaknesses of IGRAs. To date, these assays have not been widely adopted in the
United States by clinical laboratories. We have asked two experts, Thomas Alexander of Summa Health Care,
who has adopted an IGRA for M. tuberculosis detection in his laboratory, and Melissa Miller of UNC Hospitals,
who has evaluated one but has not chosen to adopt it, to explain how each reached this decision based on their
experience with the test and the data that have been published concerning IGRA.
POINT
Virtually all individuals in the United States and
many other countries of the world have undergone a
tuberculin skin test (TST). While the test has under-
gone some changes during the past 50 years, the basic
principle of the assay has not changed since the advent
of the test. We have come a long way since using cool
alcohol flames in an attempt to sterilize the needle in
between injections (T. Alexander, personal observa-
tion), and the current purified protein derivative
(PPD) extract used in the TST is a better performer
than the “old tuberculin” preparation used during the
middle of the last century. The TST does provide a
short time to results, at least compared to Mycobac-
terium tuberculosis culture; however, the test is fraught
with problems. Patients must return 48 h after the test
is given to have it read. The measurement of indura-
tion, particularly in the presence of erythema, may be
difficult for inexperienced technologists or nurses.
Many institutions follow the CDC recommendations
to give a “two-step” TST, requiring 4 separate visits
for a final result. Although the test is commonly called
a “TB” (tuberculosis) test, in reality, it may be positive
in individuals exposed to more than 30 different my-
cobacteria, including M. bovis and the Mycobacterium
avium complex (MAC) (6). Clearly it is time for a new
approach to identifying individuals exposed to TB.
The TST is an in vivo measurement of cell-mediated
immunity (CMI), sometimes referred to as delayed-type,
or “type IV,” hypersensitivity (DTH). A difficulty in clin-
ical laboratory immunology has been the absence of in
vitro assays to measure antigen-specific cell-mediated
immunity or DTH. The phenomenon of major histo-
compatibility complex (MHC) restriction has ren-
dered simple assay systems that could be used for
many individuals difficult to develop. Historically, the
few in vitro CMI assays that were available required a
48-h antigen stimulation step, followed by tritiated
thymidine uptake. The sterile culturing techniques
and the use of a radioactive reagent rendered these
assays difficult for clinical laboratories to perform.
Thus, most clinical measurements of DTH have been
performed using in vivo skin tests, such as the TST.
During the past decade, however, in vitro CMI assays
have been developed that use sensitive enzyme-linked
immunosorbent assay (ELISA) or fluorescent mea-
surements of T cell products, such as gamma inter-
feron or ATP. Currently, two in vitro CMI assays have
been approved by the U.S. Food and Drug Adminis-
tration (FDA) for diagnostic use in identifying indi-
viduals who have been exposed to M. tuberculosis.
These assays are the QuantiFERON Gold In-Tube
procedure (QFT-GIT) (Cellestis, Inc., Valencia, CA)
and the T-Spot test. (Oxford Immunotec, Malbor-
ough, MA). Both assays measure gamma interferon
production following either whole-blood (QFT-GIT)
or mononuclear cell (T-Spot) incubation with antigens
derived from M. tuberculosis. These procedures have
been given the common name of interferon gamma
release assays (IGRAs).
The IGRAs have advantages over the TST for the
patient, the physician, and the laboratory. The patient
only needs to be seen once (a two-step TST requires
four patient visits), and that is to have the blood
drawn. The QFT-GIT requires that 3 manufacturer-
provided tubes are collected. Each tube has a draw
capacity of only 1 ml. The T spot requires that a single Published ahead of print on 6 April 2011.
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7-ml heparinized Vacutainer tube be collected. The
IGRAs’ advantages for the physician and the labora-
tory include the tests’ specificity and a more objective
evaluation compared to the TST. The QFT-GIT test is
read completely objectively; the T-Spot requires a
combined objective and subjective reading. Both as-
says stimulate whole blood with the M. tuberculosis
antigen culture filtrate product 10 (CFP10) and early
secretory antigen target 6 (ESAT-6). The QFT-GIT
assay also includes a third TB antigen, TB7.7, in its
stimulating cocktail. These three antigens are found in
only 4 Mycobacterium species: M. tuberculosis, M. szul-
gai, M. kansasii, and M. marinum. Thus, the IGRAs
should be negative for patients who have received M.
bovis bacillus Calmette-Guérin (BCG) or who have
been exposed to MAC, unlike the TST, which may be
positive for those patients (6).
The IGRAs are not without disadvantages to the
laboratory, however. The reagents are more expensive
than a single- or even two-step TST. The blood for the
QFT-GIT must be appropriately incubated within 16 h
of collection. Mononuclear cells must be separated
from whole blood for the T-Spot assay within 8 h of
collection. These requirements eliminate the possibil-
ity of referring the tests to a distant facility. Superna-
tants from the QFT-GIT assay may be stored and
analyzed in bulk in an interferon ELISA at a conve-
nient time. The T-Spot has more front-end hands-on
time in the laboratory because mononuclear cells must
be isolated from the peripheral blood prior to the
incubation with antigen. The T-Spot test does not
have the more complex ELISA on the back end but
does require that technologists count the number of
“spots” on a plate, with each spot corresponding to a
positive cell. A magnifier which can be attached to a
computer makes this process relatively simple.
Thus, there are in vitro alternatives to the TST. The
most important question, however, is how the IGRAs
perform in clinical situations. A PubMed (online) search
for “QuantiFERON” in October 2010 found 416 articles
published from 2008 to 2010; thus, there is no dearth of
data. A recent meta-analysis surveyed 844 studies and
included data from 27. Sensitivities for active TB were
80% for the QuantiFERON test and 81% for the T-Spot
(8). Specificities averaged 79% and 82% for blood test-
ing by QuantiFERON and T-Spot (8). Komiya et al.
published data supporting T-Spot’s claim of better sen-
sitivity for patients with low lymphocyte counts: 81% for
T-Spot versus 39% for QuantiFERON (5). Sester et al.
conclude that although both assays are more sensitive
than the TST, neither assay is sufficiently sensitive to be
used to rule out active disease (8). In a study of 560
subjects at high risk for latent TB, the QuantiFERON
identified 51% of the subjects as positive, compared to
the TST detecting 39.4% (3). Altet-Gomez. et al. (2)
found that the IGRA tests were negative for pediatric
patients with reactive TST but documented M. avium
infection, supporting the increased specificity of the
in vitro assays. Abdhalhamid et al., using the Quanti-
FERON Gold test (QFT-G; an earlier version of the
QFT-GIT), found that the increased specificity of the
IGRA test compared to the TST resulted in a 48.8%
decrease in the overall cost to a health care system (1).
This overall decrease in cost, even though the IGRA was
more expensive than the TST, was due to BCG-vacci-
nated individuals testing negative in the IGRA. Thus,
these health care workers did not require prophylactic
treatment, resulting in a lower overall cost to the health
system. Similar results using a simulated population of
15,000 individuals exposed to TB were reported by
Deuffic-Burban et al. (4). Their study looked at cost per
year of life gained by using the TST, the TST and the
IGRA, or just the IGRA test. They found that although
the QuantiFERON test was more expensive to perform
than the TST, the cost savings per patient were over 400
Euros when the IGRA was performed (4).
Our laboratory has been performing the QuantiFERON
assay (initially the QuantiFERON Gold, currently the
QFT-GIT) for close to 4 years. We initially used it as an
adjunct to TST testing of employees. We no longer per-
form the TST for employee screening; all testing is done
with the QFT-GIT. The test is also used in patient evalu-
ations, often along with a TST. Anecdotally, our initial
evaluation of the QFT-G version proved instructive. One
individual whom we included in our evaluation was an
orthopedic surgeon who had converted to a positive TST a
few years previously and had been treated with isoniazid
(INH). He remained TST positive but was negative on the
QuantiFERON test. Further research of history could not
document a specific TB exposure but did uncover two
surgeries on an AIDS patient who had MAC within the
year prior to his TST conversion. Another physician in-
cluded in our evaluation had received the BCG vaccine as
a child and was TST positive. This individual was positive in
the QFT-G assay. Further questioning showed that this
individual had worked in a TB clinic during training. Thus,
the histories supported the QFT-G result.
We currently perform more than 3,000 QFT-GIT tests
per year. Our employee health and infection control
personnel are satisfied with the test’s performance and
have no desire to go back to the TST. However, there
are two issues that we are continuing to address. One is
the collection process, and the second is interpretation
of low-level-positive specimens.
As mentioned previously, the QFT-GIT requires that
three manufacturer-provided tubes be collected. The in-
terior of one tube is coated with the TB antigens, one
tube is coated with phytohemagglutinin as a positive
control, and one tube is uncoated as a negative control.
Each tube has a draw volume of 1.0 ml. The tubes must
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be vigorously shaken after collection to ensure exposure
of the lymphocytes to the antigen or mitogen present in
the coated tubes. This is in contrast to most phleboto-
mies, where vigorous shaking of the tubes is to be
avoided. We do see occasional low responses to the
mitogen control, invalidating the test. While this might
be due to an immune deficiency in the patient, we have
found this is often an occurrence when a new person is
collecting the specimen. Repeat collections with proper
technique yield an appropriate control value.
The second issue relates to low-positive specimens.
The QFT-GIT assay has been reported to have poor
reproducibility at low-positive interferon levels (7). We
also have observed this. We are currently evaluating our
data to determine if we should define and report a low-
positive range.
In conclusion, the advantages of IGRAs is that they
offer increased convenience, sensitivity, and specificity
compared to the TST. While the test is more expensive
than the TST, the use of an IGRA in appropriate clinical
situations can reduce the overall cost to the health care
system and lower the potential morbidity associated with
treating many patients with positive TST due to expo-
sure to nontuberculous mycobacteria.
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At our institution, the tuberculin skin test (TST) re-
mains the primary method used to screen for latent
tuberculosis infection (LTBI). In 2005, we participated
in a Centers for Disease Control and Prevention (CDC)-
sponsored study applying two generations of the Celles-
tis QuantiFERON assay (Carnegie, Australia) to LTBI
screening of patients entering an alcohol and drug treat-
ment center in North Carolina (n  429; estimated prev-
alence, 6.2%) (14). Subjects who had a prior positive
TST, history of TB, or current symptoms of TB were
excluded. Our results showed a lack of correlation of the
two different QuantiFERON assays (different test anti-
gens) with each other and with the TST. Of the positive
subjects, only 37.5% of them were positive by both in-
terferon gamma release assays (IGRAs). Indeterminate
results were completely discordant between the two
IGRAs. The QuantiFERON-TB Gold In-Tube assay
(QFT-GIT) (now FDA approved) had 1.7% indetermi-
nate samples, and these subjects were more likely to
have had five or more previous TSTs or to have been
HIV positive. Although the relatively low prevalence in
this study did not provide the statistical power needed to
analyze the IGRA results in depth, the results raised
questions about IGRA usefulness and interpretation in
low-prevalence settings, especially where there are fre-
quently repeated TSTs. The logistical difficulties in get-
ting the specimens to the laboratory from off site and the
required laboratory investment detracted somewhat
from the potential benefits of the IGRAs. Based on our
initial experience with the QuantiFERON assay, we
elected not to replace the TST with an IGRA for routine
LTBI screening. We reserve IGRA testing (which is sent
to a reference laboratory) for patients or health care
workers (HCWs) that have received the BCG vaccine or
are at risk for not returning for the TST reading. Only
1.2% of our workforce has been BCG vaccinated.
The main advantages touted for IGRAs, such as the
QFT-GIT and the T-Spot.TB (Oxford Immunotec,
Oxford, United Kingdom), are a decrease in false posi-
tives due to BCG vaccination, an increase in sensitivity
for the detection of LTBI/TB, and the elimination of
follow-up testing, such as TST reading and the two-step
baseline TST. Without a doubt, testing of individuals
that have received the BCG vaccine by an IGRA is
sound clinical practice. However, the reality is that
IGRAs are being used by physicians for a variety of
applications beyond screening immunocompetent pa-
tients at high risk for LTBI or active TB.
Screening for LTBI and active TB. It is without ques-
tion that TST reliability is dependent on the technique
and experience of both the person placing the TST and
the reader. However, if reading is standardized with the
ballpoint pen technique, the results are reasonably reli-
able, with intra- and interobserver  values of 0.70 to
0.95 (13). The comparison of performance characteris-
tics between the TST and IGRAs is complicated by the
fact that there is no gold standard for the detection of
LTBI. When TST and IGRA sensitivities have been
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evaluated, active TB is used as the pseudo-gold standard
while specificity is generally determined using low-risk
populations as a surrogate gold standard. Neither stan-
dard is appropriate for determining the performance
characteristics of the TST and IGRAs for LTBI.
Nonetheless, meta-analyses have shown the pooled
sensitivity of the TST to be 70 to 77% (69% in high-
incidence settings and 83% in low-incidence settings)
and the sensitivity of QFT-GIT to be 70 to 84% (3, 4, 11,
12). Interestingly, the T-Spot.TB cumulative sensitivity
was reported to be 88 to 90% (4, 12). Additional data
have suggested that perhaps T-Spot is the most sensitive
IGRA, but this test uses peripheral blood mononuclear
cell (PBMC) fractionation and quantification followed
by the enzyme-linked immunospot (ELISPOT) method
to measure gamma interferon-producing T cells by
counting spots in microwell plates. Because of this com-
plexity, T-Spot is not conducive to the workflow in most
nonreference clinical laboratories. In the meta-analyses
above, the specificities of QFT-GIT were 96% for BCG-
vaccinated individuals and 99% for non-BCG-vacci-
nated individuals, and the T-Spot pooled specificity was
86 to 93% from studies containing mostly BCG-vacci-
nated subjects. The specificity of the TST improved from
59% to 97% when BCG-vaccinated individuals were re-
moved from the analysis (12). Interestingly, one meta-
analysis included subjects who were suspected to have
tuberculosis but were subsequently determined to have
an alternative diagnosis (16). Specificities of 75%, 79%,
and 59% were reported for the TST, QFT-GIT, and
T-Spot, respectively. This negative-control group more
closely approximates the patients routinely tested by a
clinical laboratory and may therefore be a more accurate
reflection of test specificity.
Due to the inherent difficulties associated with com-
paring studies without head-to-head comparisons, with-
out both sensitivity and specificity being calculated, and
with variability in the TST positivity cutoff, Sadatsafavi
et al. applied statistical methods and performed a latent-
class meta-analysis for the estimation of test accuracy
(15). Their analyses showed sensitivities of 71%, 64%,
and 50% and specificities of 68%, 99%, and 91% for the
TST, QFT, and T-SPOT, respectively. TST analysis did
not take BCG vaccination into account, and only three
studies were fit for inclusion in the analysis of T-Spot;
therefore, there are limitations in this analysis. Never-
theless, the data are consistent with previous meta-anal-
yses showing suboptimal sensitivity for both the TST and
IGRAs and superior specificity of IGRAs over the TST
when BCG vaccination is not considered. In populations
with a low BCG vaccination prevalence, TST sensitivity
and specificity are not statistically different from those of
IGRAs.
Health care workers. A recent study highlighted the
questionable effectiveness of using IGRA testing as a
screening tool in HCWs in the United States (7). In this
year-long study, an increase was seen in HCWs testing
positive for LTBI by QFT-GIT testing. The annual con-
version rate was 2.5%, which represented a 25-fold in-
crease. Of the newly “converted” QFT-GIT-positive
HCWs, 49% reverted to QFT-GIT negative upon repeat
while 51% remained positive, and only two (1.5%) had a
positive TST. The mean gamma interferon response was
statistically lower for those that reverted. The authors
report that their direct costs were $436,096 for screening
of 6,530 HCWs by QFT-GIT, while the TST cost would
have been $78,360. There was an additional cost of
$85,794 related to following up the newly “converted”
HCWs determined by QFT-GIT.
These data underscore the need to consider whether
the current positivity threshold is appropriate for screen-
ing low prevalence populations. In addition, several pub-
lications have demonstrated that there is concern for the
reproducibility of IGRA results with serial testing. A
review of IGRA reproducibility data revealed that intra-
subject variability was present in all studies (n  4),
ranging in magnitude from 16% to 80%, and was most
often seen with borderline-positive IGRA results (19).
This “wobble” phenomenon around the positive thresh-
old makes interpretation difficult, particularly in the set-
ting of serial testing (Fig. 1). Some investigators have
proposed using a QFT-GIT gray zone, in which individ-
uals would be retested prior to therapy (18). The con-
version/reversion rates decreased from 11%/22% to
3.6%/4.4% and when applying a gray zone of 0.2 to 0.7
IU/ml to a medium TB incidence setting. However,
there is currently no gray zone defined in the FDA-
approved package insert for QFT-GIT.
HIV-positive patients. Since HIV-positive individuals
are at increased risk of TB reactivation, it is critical to
identify LTBI in this population. One of the perceptions
of IGRAs is that results can be reliably obtained even for
immunocompromised patients. The IGRA indetermi-
nate rate reported for HIV-positive individuals varies
greatly (1.8 to 28%) (5, 17). The rate of indeterminate
results increases when CD4 cells are 100/l (10) or
200/l (17). In HIV-positive patients with CD4 cells
at 50/l, QFT-G has been reported to be 83% sensitive
and 99% specific, but it was not accurate when CD4
cells were at 50/l (6). Not surprisingly, the T-Spot
assay is more sensitive than the QFT assays for immu-
nosuppressed patients, particularly those with lympho-
cyte counts of 500/l (81%, T-Spot; 39%, QFT-GIT),
since white blood cells are harvested and counted in the
T-Spot assay (9). However, high rates of indeterminate
results for T-Spot have also been reported (17). Of note,
individuals with an anergic TST result do not appear to
be at high risk for developing active TB (3), but this has
not been demonstrated for IGRAs.
In general, the data for HIV-positive patients indicate
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very poor correlation of results between the TST, QFT-
GIT, and T-Spot, making interpretation difficult. For
example, one study reported that positive IGRA/TST
results were discordant 72% of the time (e.g., TST/
IGRA or TST/IGRA) (10). In addition, a recent
meta-analysis of the use of IGRAs with HIV-positive
patients did not show an advantage in sensitivity of
IGRAs over the TST (1). Prospective studies are still
needed to determine if IGRA positivity is predictive of
progression to active TB among HIV-positive patients
and therefore confers a benefit over the TST.
Summary. Although other guidelines have been more
conservative (Australia, Canada, and United Kingdom),
the CDC guidelines state that an IGRA may be used in
place of the TST in all situations where a TST would be
employed (2). However, the data suggest that in areas of
low BCG vaccination, there is no advantage to using an
IGRA over the TST when there is little risk of a patient
not returning. To enable our laboratory to financially
support the routine implementation of QFT-GIT, we
would have to include the testing volume from HCW
screening. HCW compliance with TST reading is re-
quired, and the potential for a high conversion/reversion
rate makes the use of IGRAs with HCWs suboptimal.
The results between IGRAs (QFT-GIT and T-Spot)
can be discordant up to 20% of the time, making the
clinical interpretation challenging, and IGRA results
may not correlate with the TST. What is the gold stan-
dard for predicting progression to active TB? The cal-
culation of test positive predictive value (PPV) is typi-
cally based on contact investigation data, with the extent
of exposure correlated to the likelihood of a positive
test. Few studies have looked at the PPV of IGRAs for
development of TB, though contact tracing data provide
evidence that the PPV is not significantly different for
the TST and IGRAs (TST, 3.1 to 3.8%; QFT-GIT, 2.8%;
T-Spot, 3.3%) (8). While the PPV of the TST has been
studied extensively, prospective studies are still needed
to establish the PPV of IGRAs for progression to ac-
tive TB.
The conflicting and/or paucity of IGRA data on test
reproducibility, the impact of serial testing, the meaning
of discordant QFT-GIT/T-Spot or IGRA/TST results,
and the PPV indicate the critical need for carefully de-
signed prospective studies to inform evidence-based
guidelines for the routine use of IGRAs. Data are par-
ticularly limited in high-risk populations, such as chil-
dren and immunocompromised patients, who represent
those most likely to benefit from preventive therapy. The
clearest appropriate uses of IGRAs in routine clinical
care are in populations with a high prevalence of BCG
vaccination and patients at high risk for not returning for
TST follow-up. However, for the routine implementa-
tion of IGRAs for detecting LTBI and active TB in our
low-prevalence population with low rates of BCG vacci-
nation and for the screening of HCWs, we will await
FIG. 1. Schematic of the “wobble” phenomenon seen with IGRAs. The conversion and reversion points are shown as interpreted from the
manufacturers’ package inserts. The QFT-GIT assay does not have a defined gray zone, whereas the T-Spot gray zone is shown shaded (reprinted
from reference 19).
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more compelling data to indicate that the sensitivities
and/or PPV of the IGRAs are superior to those of well-
performed TSTs before investing the resources needed
to replace the TST with an IGRA institution-wide.
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● There is no diagnostic gold standard for patients thought to have latent M. tuberculosis infection (LTBI) against
which the performance of the TST versus IGRA can be judged. One of the major uses of IGRA would be to
screen health care workers and others for LTBI. When screening populations suspected of having LTBI, the TST
and IGRA have shown similar performance characteristics.
● IGRAs have very specific advantages over the TST. Because only one visit is required for IGRA versus the TST,
IGRAs are of value in patients who are likely not to return for additional medical visits in a required time frame.
These groups will include patients with higher risk for TB, such as the homeless, intravenous (i.v.) drug users, or
individuals with other difficult social situations. Second, false-positive results are much less likely in BCG-
vaccinated patients tested with IGRA.
● Both IGRAs and the TST have technical challenges in both performance and interpretation, which is probably
more pronounced with the TST. Additionally, IGRAs must be performed within a fairly tight time window,
making testing on nights and weekends in an Emergency Department setting problematic.
● IGRA is more expensive for the laboratory. The laboratory has no costs when the TST is used to screen patients.
Issues to be resolved:
● There are no good longitudinal studies with IGRA, so variability in test results, especially around the positivity
threshold, makes interpretation of this test difficult, especially for a low-prevalence population, such as health care
workers.
● Is the IGRA cost justifiable in a low-incidence population? The published data thus far appear contradictory.
● It is not known what the effect of multiple prior TST is on the accuracy of IGRAs.
● The interpretation of IGRA for HIV-infected patients with CD4 counts of less than 200/l appears to be as
problematic as the interpretation of the TST. Are IGRAs appropriate for HIV-infected patients with low CD4
counts? The IGRAs attempt to overcome this issue by including the phytohemagglutinin (PHA) control to
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provide an indication of immune capabilities, however. The T-Spot assay also includes a mononuclear cell
concentration step. The TST uses a lower induration measurement in patients with known immunodeficiency as
an indicator of true positivity. Which of these parameters best overcomes the issues associated with low immune
function is an unanswered question.
Peter Gilligan
Editor, Point-Counterpoint
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